These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35155990)

  • 21. Edetate Disodium as a Polysorbate Degradation and Monoclonal Antibody Oxidation Stabilizer.
    Yarbrough M; Hodge T; Menard D; Jerome R; Ryczek J; Moore D; Baldus P; Warne N; Ohtake S
    J Pharm Sci; 2019 Apr; 108(4):1631-1635. PubMed ID: 30502482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations.
    Chiu J; Valente KN; Levy NE; Min L; Lenhoff AM; Lee KH
    Biotechnol Bioeng; 2017 May; 114(5):1006-1015. PubMed ID: 27943242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-Throughput, Fluorescence-Based Esterase Activity Assay for Assessing Polysorbate Degradation Risk during Biopharmaceutical Development.
    Bhargava AC; Mains K; Siu A; Gu J; Zarzar J; Yi L; Yuk IH
    Pharm Res; 2021 Mar; 38(3):397-413. PubMed ID: 33655394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases.
    Zhang S; Riccardi C; Kamen D; Reilly J; Mattila J; Bak H; Xiao H; Li N
    Pharm Res; 2022 Jan; 39(1):75-87. PubMed ID: 34981317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis methods of polysorbate 20: A new method to assess the stability of polysorbate 20 and established methods that may overlook degraded polysorbate 20.
    Khossravi M; Kao YH; Mrsny RJ; Sweeney TD
    Pharm Res; 2002 May; 19(5):634-9. PubMed ID: 12069166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a selective marker-based quantification of polysorbate 20 in biopharmaceutical formulations using UPLC QDa detection.
    Evers DH; Schultz-Fademrecht T; Garidel P; Buske J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122287. PubMed ID: 33069954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method.
    Zhang S; Riccardi C; Kamen D; Xiao H; Li N
    Anal Biochem; 2022 Jan; 637():114472. PubMed ID: 34801481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of Polysorbates.
    Wuchner K; Yi L; Chery C; Nikels F; Junge F; Crotts G; Rinaldi G; Starkey JA; Bechtold-Peters K; Shuman M; Leiss M; Jahn M; Garidel P; de Ruiter R; Richer SM; Cao S; Peuker S; Huille S; Wang T; Le Brun V
    J Pharm Sci; 2022 May; 111(5):1280-1291. PubMed ID: 35192858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations.
    Katz JS; Chou DK; Christian TR; Das TK; Patel M; Singh SN; Wen Y
    J Pharm Sci; 2022 Apr; 111(4):919-932. PubMed ID: 34883096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the Future.
    Wuchner K; Yi L; Chery C; Nikels F; Junge F; Crotts G; Rinaldi G; Starkey JA; Bechtold-Peters K; Shuman M; Leiss M; Jahn M; Garidel P; de Ruiter R; Richer SM; Cao S; Peuker S; Huille S; Wang T; Brun VL
    J Pharm Sci; 2022 Nov; 111(11):2955-2967. PubMed ID: 36002077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydrolytic polysorbate 20 degradation - Sensitive detection of free fatty acids in biopharmaceuticals via UPLC-QDa analytics with isolator column.
    Evers DH; Carle S; Lakatos D; Hämmerling F; Garidel P; Buske J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1174():122717. PubMed ID: 33975273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring Lipolytic Activity to Support Process Improvements to Manage Lipase-Mediated Polysorbate Degradation.
    Jahn M; Zerr A; Fedorowicz FM; Brigger F; Koulov A; Mahler HC
    Pharm Res; 2020 Jun; 37(6):118. PubMed ID: 32495187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating the Influence of Polysorbate 20/80 and Polaxomer P188 on the Surface & Interfacial Properties of Bovine Serum Albumin and Lysozyme.
    Begum F; Amin S
    Pharm Res; 2019 May; 36(7):107. PubMed ID: 31111248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous quantification of polysorbate 20 and poloxamer 188 in biopharmaceutical formulations using evaporative light scattering detection.
    Paschen CA; Klemm D; Graf T; Kopf R; Pinto C; Müller C; Bell CH; Pfaff J
    J Pharm Biomed Anal; 2021 Jan; 192():113640. PubMed ID: 33002754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability Indicating Method for Polysorbate 80 in Protein Formulations.
    Webster GK; Chang JC; Heflin JL
    J Chromatogr Sci; 2021 Aug; 59(8):706-713. PubMed ID: 33367524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of mono- and poly-ester fractions on polysorbate quantitation using mixed-mode HPLC-CAD/ELSD and the fluorescence micelle assay.
    Lippold S; Koshari SHS; Kopf R; Schuller R; Buckel T; Zarraga IE; Koehn H
    J Pharm Biomed Anal; 2017 Jan; 132():24-34. PubMed ID: 27693757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension to Predict Surfactant Requirements for Biological Formulations.
    Vargo KB; Stahl P; Hwang B; Hwang E; Giordano D; Randolph P; Celentano C; Hepler R; Amin K
    Mol Pharm; 2021 Jan; 18(1):148-157. PubMed ID: 33253579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.